Business Context and Reporting Period
This Form 8-K filing by Akebia Therapeutics, Inc. (AKBA) reports a material definitive agreement entered into on February 28, 2022, and filed on February 28, 2023. The Company is a biopharmaceutical firm focused on developing treatments for kidney disease, with its principal executive offices in Cambridge, Massachusetts.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a contractual amendment regarding manufacturing supply.
Material Changes and Agreements
The Company's wholly-owned subsidiary, Keryx Biopharmaceuticals, Inc., amended its Master Manufacturing Services and Supply Agreement with Siegfried Evionnaz SA (Amendment No. 5). Key terms include:
- Commitment: Akebia agreed to purchase a minimum quantity of drug substance for its product Auryxia at a predetermined price.
- Term Extension: The agreement term now expires on December 31, 2024.
- Option: The Company holds an option to extend the agreement through December 31, 2026, contingent on providing 12 months' prior written notice.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future performance, or specific risk factors beyond the obligations inherent in the new supply agreement. The full text of the Amendment is expected to be filed as an exhibit to the Quarterly Report on Form 10-Q for the period ending March 31, 2023.
Investor Verification Checklist
- Verify the specific minimum quantity and predetermined price for Auryxia drug substance in the full Amendment text.
- Review the upcoming Form 10-Q for the quarter ended March 31, 2023, for the complete exhibit and any related financial impact disclosures.
- Assess the impact of the extended supply commitment on future cash flow and working capital requirements.